Predictors of methamphetamine psychosis: history of ADHD-relevant childhood behaviors and drug exposure
- PMID: 23896355
- PMCID: PMC3818411
- DOI: 10.1016/j.psychres.2013.06.030
Predictors of methamphetamine psychosis: history of ADHD-relevant childhood behaviors and drug exposure
Abstract
The goal of this study was to extend our previous research that reported a significant association between Attention Deficit Hyperactivity Disorder (ADHD)-relevant childhood behaviors and the frequency of methamphetamine (MA)-induced psychotic symptoms in an expanded sample. 190 participants who met DSM-IV criteria for MA dependence were administered the Methamphetamine Experience Questionnaire that assessed MA-induced psychosis. Data related to MA exposure, comorbid drug use, education, familial psychiatric history and assessments of ADHD-relevant childhood behaviors as measured by the Wender Utah Rating Scale (WURS) were collected. Although WURS scores did not differ between 145 MAP+ and 45 MAP- subjects, MAP+ subjects with higher WURS scores were significantly more likely to report more frequent psychosis. Although mean daily MA dosage did not differ between the MAP+ and MAP- subjects, MAP+ subjects who consumed larger doses of MA were significantly more likely to experience frequent psychosis. These data suggest that ADHD-relevant childhood behaviors may interact with MA exposure to reflect a neurobiological vulnerability related to the emergence of frequent MA-induced psychotic symptoms. These results may elucidate factors that contribute to the psychiatric sequelae of MA abuse.
Keywords: ADHD; Attention; Methamphetamine; Predictors; Prefrontal cortex; Psychosis; Substance abuse.
© 2013 Elsevier Ireland Ltd. All rights reserved.
Figures

Similar articles
-
Preliminary evidence of behavioral predictors of recurrent drug-induced psychosis in methamphetamine abuse.Psychiatry Res. 2008 Jan 15;157(1-3):273-7. doi: 10.1016/j.psychres.2007.04.018. Epub 2007 Oct 24. Psychiatry Res. 2008. PMID: 17928066
-
Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders.J Dual Diagn. 2020 Apr-Jun;16(2):208-217. doi: 10.1080/15504263.2020.1714099. Epub 2020 Jan 26. J Dual Diagn. 2020. PMID: 31984872
-
Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders.Psychiatry Res. 2017 May;251:349-354. doi: 10.1016/j.psychres.2017.02.028. Epub 2017 Feb 13. Psychiatry Res. 2017. PMID: 28282630
-
A systematic review of risk factors for methamphetamine-associated psychosis.Aust N Z J Psychiatry. 2018 Jun;52(6):514-529. doi: 10.1177/0004867417748750. Epub 2018 Jan 16. Aust N Z J Psychiatry. 2018. PMID: 29338289
-
Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis.Ann N Y Acad Sci. 2004 Oct;1025:279-87. doi: 10.1196/annals.1316.035. Ann N Y Acad Sci. 2004. PMID: 15542728 Review.
Cited by
-
Factors Associated with Psychotic and Depressive Symptoms in Methamphetamine Users.Iran J Psychiatry. 2024 Jan;19(1):1-10. doi: 10.18502/ijps.v19i1.14334. Iran J Psychiatry. 2024. PMID: 38420276 Free PMC article.
-
A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology.Front Psychiatry. 2018 Oct 10;9:491. doi: 10.3389/fpsyt.2018.00491. eCollection 2018. Front Psychiatry. 2018. PMID: 30364176 Free PMC article. Review.
-
A Review of Risk Factors for Methamphetamine-Related Psychiatric Symptoms.Front Psychiatry. 2018 Nov 16;9:603. doi: 10.3389/fpsyt.2018.00603. eCollection 2018. Front Psychiatry. 2018. PMID: 30519197 Free PMC article. Review.
-
Attenuation Effect of Cannabinoid Type 1 Receptor Activation on Methamphetamine-Induced Neurodegeneration and Locomotion Impairments among Male Rats.Addict Health. 2017 Fall;9(4):206-213. Addict Health. 2017. PMID: 30574283 Free PMC article.
-
A Study of the Prevalence of Psychiatric Disorders in Patients with Methamphetamine-Induced Psychosis.Addict Health. 2015 Winter-Spring;7(1-2):37-46. Addict Health. 2015. PMID: 26322209 Free PMC article.
References
-
- Abi-Dargham A, Kegeles LS, Martinez D, Innis RB, Laruelle M. Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: Results from a large cohort. European Neuropsychopharmacology. 2003;13:459–468. - PubMed
-
- Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M. Increased baseline occupancy of d2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:8104–8109. - PMC - PubMed
-
- Addington J, Duchak V. Reasons for substance use in schizophrenia. Acta Psychiatrica Scandinavica. 1997;96:329–333. - PubMed
-
- Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. Journal of Psychiatric Research. 1974;11:13–23. - PubMed
-
- Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis--preliminary observations. Biological Psychiatry. 1970;2:95–107. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous